Business Context and Reporting Period
HealthCor Catalio Acquisition Corp. filed this Form 8-K on July 8, 2021, reporting entry into a Transaction Support Agreement related to its proposed business combination with Hyperfine, Inc. and Liminal Sciences, Inc. The filing is a transaction update, not a periodic financial report.
Transaction and Key Terms
- Dr. Jonathan M. Rothberg and affiliated stockholders of Hyperfine and Liminal agreed to support the proposed Business Combination Agreement dated July 7, 2021.
- Following effectiveness of the related Form S-4 registration statement, the supporting stockholders agreed to deliver written consents approving the Business Combination and related documents within two business days, subject to the agreement’s terms.
- The covered holdings represent more than 74% of Hyperfine’s aggregate voting power and more than 95% of Liminal’s aggregate voting power, each calculated on an as-converted basis.
- The supporting stockholders are restricted from soliciting or participating in activities having the effect of soliciting a competing acquisition proposal.
- The Transaction Support Agreement was filed as Exhibit 10.1.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, valuation, consideration, or other operating financial metrics.
Material Changes Versus Prior Period
No comparable-period financial information or operating results are presented. The material development is the execution of the Transaction Support Agreement in connection with the proposed Business Combination.
Outlook, Risks, and Contingencies
- Completion of the transaction remains subject to the effectiveness of the Form S-4 registration statement, shareholder approvals and other conditions described in the Business Combination Agreement.
- The filing states that the preliminary and definitive proxy statement/prospectus and related SEC filings will contain additional information about the transaction, participants and their interests.
- The transaction may not be completed, and the filing does not provide a closing date or quantify transaction-related risks, financing requirements or potential dilution.
- The Form 8-K is not itself a proxy solicitation, offer to sell, or solicitation of an offer to buy securities.
Facts Investors Should Verify
- Review the Form S-4, proxy statement/prospectus and Business Combination Agreement for consideration, ownership structure, financing, dilution, closing conditions and termination rights.
- Confirm the final shareholder voting and consent requirements and whether the supporting stockholder commitments remain effective.
- Review Hyperfine’s and Liminal’s financial statements, operating results, cash needs and risk factors when filed or incorporated into the registration materials.
- Check subsequent SEC filings for transaction amendments, shareholder approvals, redemptions, financing arrangements and closing status.